Target α4β7 x IL-23 therapy(Vial Health Technology Inc)

N/A

Report date: 2025/10/31 15:38:23

Base Information

Drug NameTarget α4β7 x IL-23 therapy(Vial Health Technology Inc)

Drug Alias Nameanti-α4β7/anti-IL-23 bispecific monoclonal antibody(Vial Health Technology Inc)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionIntegrin alpha-4/beta-7 modulatorsInterleukin-23 modulators

TargetsIntegrin alpha-4/beta-7Interleukin-23

Therapy Area/IndicationsInflammatory Bowel Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesVial Health Technology Inc

China Registration ClassN/A

Develop Information

Active CompaniesVial Health Technology Inc

Inactive CompaniesN/A

Active IndicationsInflammatory Bowel Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A